Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TEC | P42680 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906150 | 0.93 | PARP1 (0.38) | PARP1EGFRTECBTKCASP1 | |
| SCHEMBL13544719 | 0.84 | POLB (0.47) | CASP1POLBKMT2A | |
| SCHEMBL18412776 | 0.83 | POLB (0.36) | PARP1POLBKMT2APDE10A | |
| SCHEMBL28994011 | 0.79 | SMN1; SMN2 (0.44) | POLB | |
| SCHEMBL30408412 | 0.78 | CAMKK2 (0.44) | POLBKMT2A | |
| SCHEMBL566098 | 0.76 | SCN9A (0.42) | PARP1CASP1POLBKMT2A | |
| SCHEMBL13544720 | 0.75 | KDM4E (0.45) | CASP1KMT2AATM | |
| SCHEMBL31325007 | 0.75 | KDM4E (0.45) | CASP1KMT2AATM | |
| SCHEMBL893997 | 0.74 | KMT2A (0.42) | PARP1CASP1POLBKMT2AATM | |
| SCHEMBL22092996 | 0.73 | SMN1; SMN2 (0.57) | KMT2ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103888-A1 | PYRIMIDIN-2(1H)-ONE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海青润医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| CN-122036626-A | Pyrimidine-2 (1H) -ketone derivative, pharmaceutical composition and application thereof | 上海青润医药科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | disclosed |
| CN-113166078-B | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4168394-A1 | AMIDOPYRIMIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867541-A | Aminopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| WO-2021259815-A1 | AMIDOPYRIMIDONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-30 | — | — | WO | disclosed |
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | PARP1 536/4885EGFR 4378/4885TEC 3014/4885 |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | PARP1 536/4885EGFR 4378/4885TEC 3014/4885 |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | PARP1 536/4885EGFR 4378/4885TEC 3014/4885 |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | PARP1 1051/4885EGFR 2182/4885TEC 803/4885 |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | PARP1 536/4885EGFR 4378/4885TEC 3014/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | PARP1 536/4885EGFR 4378/4885TEC 3014/4885 |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | PARP1 1051/4885EGFR 2182/4885TEC 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.